ARCT - Arcturus Therapeutics Holdings Inc. Looks to Continue to Trade Above its Annual-High Share Price Today
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded today at $129.60, eclipsing its 52-week high. So far today approximately 33.7 million shares have been exchanged, as compared to an average 30-day volume of 547,000 shares.
Arcturus Therapeutics Holdings Inc. has overhead space with shares priced $27.58, or 8.6% below the average consensus analyst price target of $30.19.
Arcturus Therapeutics Holdings Inc. share prices have moved between a 52-week high of $65.00 and the current low of $4.19 and are currently at $27.58 per share.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer